Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Peritoneal Mesotheliomas Clinical Trial

Official title:

Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01812148
• Other study ID #: Maisonneuve Rosemont Hospital
• Secondary ID: 12112
• Status: Completed
• Phase: N/A
• First received: March 12, 2013
• Last updated: March 15, 2013
• Start date: January 2012
• Est. completion date: March 2013

Study information

• Verified date: March 2013
• Source: Maisonneuve-Rosemont Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Observational

Clinical Trial Summary

Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.

Description:

Observation of primary outcome:

• Overall Survival

• Disease-free survival

Influencing factors that will be observe:

• Sex

• Blood loss

• Time of surgery

• Number of resection and anastomosis

• Peritoneal Index (PI score)

• Cytoreductibility (CCR score)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: March 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Peritoneal mesothelioma

Exclusion Criteria:

• Non resectable disease

Study Design

Observational Model: Case-Crossover, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Fever
• Mesothelioma
• Peritoneal Mesotheliomas

Intervention

Procedure:
• Cytoreductive surgery and HIPEC
Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent

Locations

Country	Name	City	State
Canada	Maisonneuve Rosemont Hospital	Montréal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Maisonneuve-Rosemont Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival		5 years	No
Secondary	Disease-Free survival		5 years	No